Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: A retrospective chart review

Basit Öğe Kaydı
dc.contributor.authorErcan E.S.
dc.contributor.authorAkyol Ardic U.
dc.contributor.authorKabukcu Basay B.
dc.contributor.authorErcan E.
dc.contributor.authorBasay O.
dc.date.accessioned2019-10-26T21:33:03Z
dc.date.available2019-10-26T21:33:03Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractThe DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 1994, American Psychiatric Association) describes attention deficit hyperactivity disorder (ADHD) as a heterogeneous disorder; providing diagnostic criteria for three subtypes: hyperactive/impulsive (ADHD/HI), inattentive (ADHD/I), and combined type (ADHD/C). Differences among the subtypes are well defined, but there may be also differences in terms of treatment responses. The aim of this study is to assess the responses of ADHD/I and ADHD/C to atomoxetine treatment. The medical records of the January-June 2012 term, first time referrals to outpatient clinic, were reviewed, and 37 ADHD diagnosed primary school age children (18 ADHD/I, 19 ADHD/C) that were treated with atomoxetine were determined. Thirty-five of them who completed 8 weeks of treatment duration were recruited for the study. The children with an ADHD medication use history in 2 months time prior to onset of treatment and/or the children receiving additional psychopharmacologic treatment to atomoxetine were excluded. Baseline and eighth week assessment, records were evaluated. Efficacy assessments included Turgay DSM-IV ADHD Screening and Rating Scale parent and teacher forms (T-DSM-IV) and Clinical Global Impression Scale-Severity and Improvement subscales. Safety assessments included laboratory and body weight assessments, ECG, heart rate, and blood pressure evaluations (baseline and eighth week) along a scale filled by the parents at the eighth week to review side effects. Atomoxetine was found to be effective in both ADHD/I and ADHD/C groups. Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. Mean difference in 8-week time in T-DSM-IV hyperactivity subscale and total scores of parent and teacher forms; inattention subscale scores of only parent forms and the CGI- severity subscale scores; differed significantly among the ADHD/I and ADHD/C groups; that ADHD/C types responded better to medication. Results of this study revealed that atomoxetine is effective both in ADHD/I and ADHD/C subtypes. ADHD/C types may be responding better to atomoxetine treatment than the ADHD/I subtypes. © 2013 Springer-Verlag Wien.en_US
dc.identifier.doi10.1007/s12402-013-0111-0en_US
dc.identifier.endpage385en_US
dc.identifier.issn1866-6116
dc.identifier.issue4en_US
dc.identifier.pmid23737214en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage377en_US
dc.identifier.urihttps://doi.org/10.1007/s12402-013-0111-0
dc.identifier.urihttps://hdl.handle.net/11454/17796
dc.identifier.volume5en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofADHD Attention Deficit and Hyperactivity Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectADHDen_US
dc.subjectADHD/HIen_US
dc.subjectADHD/Ien_US
dc.subjectAtomoxetineen_US
dc.titleAtomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: A retrospective chart reviewen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu